Voloridge Investment Management
AQST icon

Voloridge Investment Management’s Aquestive Therapeutics AQST Stock Holding History

Voloridge Investment Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-194,105
Closed -$1.25M – 993
2025
Q4 		$1.25M Buy
+194,105
New +$1.21M ﹤0.01% 981

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Voloridge Investment Management's AQST Position: Q1 2026 in Review

Voloridge Investment Management sold out of Aquestive Therapeutics (AQST) in Q1 2026, closing a stake of 194,105 shares — an estimated $1.25M sold.

Voloridge Investment Management first reported a position in AQST in Q4 2025 and held it in 1 quarter. The position peaked at $1.25M in Q4 2025. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Voloridge Investment Management reported no remaining Aquestive Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Voloridge Investment Management sold 194,105 Aquestive Therapeutics shares in Q1 2026, an estimated $1.25M.
  • Voloridge Investment Management first reported a position in Aquestive Therapeutics in Q4 2025 and held it in 1 quarter.
  • Voloridge Investment Management's Aquestive Therapeutics position peaked at $1.25M in Q4 2025.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Voloridge Investment Management's 13F filing for Q1 2026, filed 15 May 2026.